Related Experiment Videos
Multidrug resistance in pediatric oncology
1Division of Pediatrics, University of Texas M.D., Anderson Cancer Center, Houston, USA.
Investigational New Drugs
|January 1, 1996
Summary
Multidrug resistance (MDR) is a key challenge in childhood cancer treatment, contributing to therapeutic failure. Further research is needed to clarify MDR
Area of Science:
- Pediatric Oncology
- Molecular Biology
- Pharmacology
Background:
- Childhood cancer survival has improved with multimodal therapy.
- However, 20-30% of children still succumb to cancer or treatment complications.
- Treatment resistance, particularly multidrug resistance (MDR), limits further survival gains.
Purpose of the Study:
- To review the role of multidrug resistance (MDR) in pediatric malignancies.
- To assess the current understanding of MDR mechanisms in childhood cancers.
- To evaluate the potential for MDR-targeted therapies.
Main Methods:
- Review of existing literature on MDR in childhood cancers.
- Analysis of studies investigating P-glycoprotein and multidrug resistance-associated proteins.
- Examination of clinical resistance patterns in various pediatric malignancies.
Main Results:
- Multidrug resistance (MDR) is implicated in treatment failure in pediatric cancers.
- The precise role of P-glycoprotein in MDR is controversial across different childhood malignancies.
- Emerging evidence suggests multidrug resistance-associated proteins may play a role, especially in neuroblastoma.
Conclusions:
- The exact role of MDR in pediatric malignancies requires further investigation with standardized methods.
- Targeted clinical trials for MDR reversal are premature due to controversial findings and lack of selective inhibitors.
- Further research is essential to elucidate MDR mechanisms and develop effective therapeutic strategies.